Navigation Links
Thoratec Announces Filing of PMA Seeking Destination Therapy Approval for HeartMate II(R)
Date:4/20/2009

t not exclusively those addressing future performance or timelines for regulatory approvals, contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements can be identified by the words, "believes," "views," "expects," "plans," "hopes," "could," "will," and other similar words. Actual results, events or performance could differ materially from these forward-looking statements based on a variety of factors, many of which are beyond Thoratec's control. Therefore, readers are cautioned not to put undue reliance on these statements. Investors are cautioned that all such statements involve risks and uncertainties, including risks related to regulatory approvals, the development of new markets including Destination Therapy, the growth of existing markets for our products, customer and physician acceptance of Thoratec products, changes in the mix of existing markets for our products, the results of enrollment in and timing of clinical trials, including the HeartMate II, the effects of FDA regulatory requirements and the effects of healthcare reimbursement and coverage policies. Forward-looking statements contained in this press release should be considered in light of these factors and those factors discussed from time to time in Thoratec's public reports filed with the Securities and Exchange Commission, such as those discussed under the heading "Risk Factors" in Thoratec's most recent annual report on Form 10-K and as may be updated in subsequent SEC filings. These forward-looking statements speak only as the date hereof. Thoratec undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE Thoratec Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Thoratec Announces HeartMate II(R) PMA Will be Reviewed by FDA Advisory Panel
2. Thoratec Presentation at Bear Stearns Conference To Be Webcast
3. Thoratec Announces Appointment of Steven H. Collis to Board of Directors
4. Thoratec Presentation at JP Morgan Conference to be Webcast
5. Thoratec Reports 10 Percent Increase in Fiscal 2007 Revenues; Fourth Quarter Revenues Largest in Company History
6. Thoratec Schedules Third Quarter 2008 Conference Call, Webcast
7. Thoratec Reports 44 Percent Increase in Third Quarter Revenues
8. Thoratec Presentation at J.P. Morgan Conference to be Webcast
9. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
10. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
11. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/23/2014)... 2014 Dr. Carl Peck, ... today that Janet B. Arrowsmith, MD, has joined ... Partners Premier Experts are top tier consultants whose ... extraordinary value to the company’s clients. Premier Experts ... help clients successfully develop their medical products, pursue ...
(Date:8/22/2014)... (PRWEB) August 23, 2014 This ... current state of the Papain industry in Global ... of the industry, including definitions, applications and industry ... market analysis are provided with a focus on ... market. A comparison between the international and Chinese ...
(Date:8/22/2014)... Today the Academy of Model Aeronautics (AMA) ... of Appeals for the D.C. Circuit challenging the FAA’s Interpretation ... Federal Register on June 25, 2014. , The AMA ... text and intent of the FAA Modernization and Reform Act ... on any new rules or regulations regarding model aircraft that ...
(Date:8/22/2014)... ON , Aug. 22, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ... six month periods ended June 30, 2014.  Biorem,s complete 2014 second quarter ... Financial Summary:Three-months ended June 30, , Six-months ended ... , 2014 , 2013 , 2014 ... , 4,433 , 9,195 Gross profit , 56 ...
Breaking Biology Technology:Noted Epidemiologist and Former FDA Deputy Director Janet B. Arrowsmith, MD, Joins NDA Partners as a Premier Expert Consultant 2Papain Industry Global & China Development Trend and Proposals Analysis Research Report Available at DeepResearchReports.com 2Papain Industry Global & China Development Trend and Proposals Analysis Research Report Available at DeepResearchReports.com 3AMA Files Petition for Review of FAA’s Interpretive Rule 2Biorem Reports 2014 Second Quarter Results 2Biorem Reports 2014 Second Quarter Results 3
... Va., Aug. 13 According to new research ... market,research and consulting firm serving the life science ... must innovate to find new ways to,demonstrate customer ... equipment manufacturer (OEM), in-house and a,combination of all ...
... the,appointment of David A. Mann to the Company,s Board ... Board,s audit committee., "Dave,s years of executive management ... an invaluable asset to Omeros,",stated Gregory Demopulos, M.D., Chairman ... our Board, and I expect that he will play ...
... 2:00 p.m. CET, AMSTERDAM, August 13 Amsterdam Molecular,Therapeutics ... therapy,today reported its results for the first half year of ... trial for Glybera(R) (AMT-011) for Hyperlipoproteinemia type I ... - License for treatment of Duchenne Muscular Dystrophy from ...
Cached Biology Technology:BioInformatics, LLC Offers Solutions for Optimizing Service and/or Maintenance Contracts 2BioInformatics, LLC Offers Solutions for Optimizing Service and/or Maintenance Contracts 3Omeros Appoints David A. Mann to its Board of Directors 2Amsterdam Molecular Therapeutics Reports Half Year Results 2008 2Amsterdam Molecular Therapeutics Reports Half Year Results 2008 3Amsterdam Molecular Therapeutics Reports Half Year Results 2008 4
(Date:8/22/2014)... , August 22, 2014 /PRNewswire/ ... http://www.researchandmarkets.com/research/mtm27l/biometrics_market ) has announced the addition ... America 2014-2018"  report to their offering.  ... , ,Biometrics is a technology that ... based on their physical or behavioral ...
(Date:8/22/2014)... Thomson Reuters , a leading source of information ... the University of California, Riverside in its 2014 list ... our times." , To generate the list, the company ... researchers whose published work has had enormous impact. , ... 3,200 individuals who published the greatest number of highly ...
(Date:8/22/2014)... Jolla, CA Research presented at the 29th ... being developed by Hera Therapeutics Inc. combats three ... cause 70 percent of all cervical cancer. , ... HTI-1968 blocked the replication of HPV-16, HPV-18 and ... and Thomas Broker, Ph.D., who presented the findings ...
Breaking Biology News(10 mins):Biometrics Market in North America 2014-2018: Key Vendors are 3M Cogent, Cross Match, NEC and Safran SA 2Biometrics Market in North America 2014-2018: Key Vendors are 3M Cogent, Cross Match, NEC and Safran SA 35 UC Riverside scientists among world's most influential scientific minds 2
... have linked an overactive response by one of the immune ... cells to the onset of biliary atresia in infants, ... damage and death. Researchers at Cincinnati Children,s Hospital Medical ... cells attack bile duct tissues lessens damage and may be ...
... temporal variability in crop yields has implications for sustainable ... are projected with global climate change. Many long-term ... study looked at stability of yields and whether cropping ... poor- and high- yielding years. K.K. Grover ...
... Singapore and Washington DC (July 20, 2009) Genetic testing ... patient, and the results of the consumers, response can affect ... testing, according to a position paper from the American College ... 2009 issue of the Journal of Clinical Pharmacology . ...
Cached Biology News:Scientists link immune system's natural killer cells to infant liver disease 2Genetic tests advertised directly to the consumer 2
... Turner (1997). • This book describes ... the production of high-quality antibodies, the ... standardisation of antibodies and antigens, the ... enzyme immunoassays for detecting cell-surface molecules ...
... The 1-D PAGE ... Kit for Targeted Protein ... SDS PolyAcrylamide Gel Electrophoresis ... chemistry, and cleavable-linker technology ...
Thermal Printer Paper for Monolight(tm) Luminometer 1 each...
Large-fragment, single-stranded carrier DNA of the highest quality, perfectly suited for all types of yeast transformation....
Biology Products: